Circular RNAs for diagnosis of depression and prediction of response to antidepressant treatment
AssigneesUNM Rainforest Innovations, Board of Regents, The University of Texas System
InventorsNikolaos Mellios, Madhukar H. Trivedi
Life of this patent
Estimating the term…
Abstract
A plurality of circular RNAs (circRNAs) the expression of which is correlated with diagnosis for Major Depressive Disorder (MDD) and Bipolar Disorder (BD) and response to treatment with various antidepressants is provided. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment, and/or monitoring of brain disorders such as MDD and BD.
Claims19
A method for assessing major depressive disorder (MDD) or bipolar disorder (BD) in a subject comprising:
- obtaining a first sample from the subject;
- assaying the first sample using probes and/or primers configured to identify the presence of and/or amplify one or more brain disorder-associated circRNA biomarkers;
- producing an expression profile of the one or more brain disorder-associated circRNA biomarkers based on the assay;
- comparing the expression profile to a control expression profile or to an expression profile from a second sample obtained from the subject after administration of an antidepressant treatment;
- and administering, changing, or discontinuing an antidepressant therapy for said subject based on the differential expression of said brain disorder-associated circRNA biomarkers in said first sample compared to said control or to said second sample;
- and wherein the antidepressant therapy is selected from:
- administering a Selective Serotonin Reuptake Inhibitors (SSRIs), administering a serotonin and norepinephrine reuptake inhibitors (SNRIs), administering a Monoamine oxidase inhibitors (MAOIs), or any combination thereof;
- and wherein the brain disorder-associated circRNA biomarkers comprise one or more circRNAs selected from SEQ ID NOs:
- 1-45 or 47-241.
A method for assessing MDD or BD in a subject comprising:
- providing a sample from the subject;
- assaying the sample using primers configured to identify the presence of and/or amplify one or more brain disorder-associated circRNA biomarkers;
- and determining whether the sample has altered levels of the one or more brain disorder-associated circRNAs, or a different expression profile of the one or more brain disorder-associated circRNAs, relative to a control representing levels of the one or more brain disorder-associated circRNAs, or an expression profile of the one or more brain disorder-associated circRNAs, in non-MDD or non-BD humans,
- wherein the primers include a sequence that spans a splice junction of any of the one or more brain disorder-associated circRNA biomarkers in an asymmetric manner,
- wherein the brain disorder-associated circRNA biomarkers comprise one or more circRNAs selected from SEQ ID NOs:
- 1-45 or 47-241.
A method of treating a MDD or BD condition in a patient who is predicted to benefit or not to benefit from therapeutic administration of an antidepressant treatment comprising:
- detecting in a first sample of the patient the expression levels of one or more MDD/BD or antidepressant response/treatment-associated circRNA biomarkers to establish an expression profile of said patient;
- administering to said patient an antidepressant treatment to treat MDD or BD wherein the antidepressant treatment medication is selected from the group consisting of:
- Selective Serotonin Reuptake Inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants;
- detecting in a second sample of said patient the expression levels of said MDD- or BD-associated circRNA biomarkers after administration of said antidepressant treatment;
- and
- correlating the levels of expression in said first and second samples to determine if the antidepressant treatment is effective at treating the condition, and continuing to administer the antidepressant treatment to treat MDD or BD based on said correlation, or stopping administering the antidepressant treatment to treat MDD or BD, or administering a different antidepressant treatment to treat MDD or BD,
- wherein the circRNA biomarkers comprise one or more circRNAs selected from SEQ ID NOs:
- 1-45 or 47-241.
Dependencies are inferred from the claim text.